drugset / Trial / NCT05768035
Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide
NaSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitors (HTLP)) injection to accelerate immune reconstitution after haploidentical hematopoietic stem cell transplantation (HSCT) with post-transplant cyclophosphamide (PT-Cy) in adult patients with hematological malignancies.
Timeline
- Start
- 2023-06-06
- Primary completion
- 2025-07
- Completion
- 2026-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SMART101 | Cell therapy | 1.5e+06 cells/kg | — |
| Subject | SMART101 | Cell therapy | 4.5e+06 cells/kg | — |
| Subject | SMART101 | Cell therapy | 9e+06 cells/kg | — |